MARKET

REPH

REPH

Recro Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.170
+0.020
+0.48%
After Hours: 4.170 0 0.00% 16:00 07/10 EDT
OPEN
4.140
PREV CLOSE
4.150
HIGH
4.270
LOW
4.067
VOLUME
128.82K
TURNOVER
--
52 WEEK HIGH
19.21
52 WEEK LOW
4.067
MARKET CAP
98.27M
P/E (TTM)
-85.4508
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average REPH stock price target is 10.50 with a high estimate of 12.00 and a low estimate of 9.00.

EPS

REPH News

More
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 14h ago
Is Recro Pharma Inc (REPH) A Good Stock To Buy?
Insider Monkey · 4d ago
Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies
GlobeNewswire · 06/11 15:00
Recro Gainesville Reports Is Ready With Available Capacity To Secure New Oral Drug Product Manufacturing Contracts For Its Contract Development, Manufacturing Organization Facilities In Gainesville, Georgia
Benzinga · 06/11 14:02
Recro Pharma (REPH) in Focus: Stock Moves 7.6% Higher
Zacks · 06/10 13:31
3 Penny Stocks That Could Climb Over 140%
TipRanks · 06/08 14:49
Edited Transcript of REPH earnings conference call or presentation 11-May-20 12:00pm GMT
Thomson Reuters StreetEvents · 06/01 01:40
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14)
Benzinga · 05/15 11:49

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About REPH

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
More

Webull offers kinds of Recro Pharma Inc stock information, including NASDAQ:REPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REPH stock methods without spending real money on the virtual paper trading platform.